Recommendation of the President #HPP #48aa – Prevention of lymphedema after breast cancer treatment
Recommendation No. 179/2025 of 28 November 2025, of the President of the Agency for Health Technology Assessment and Tariff System on recommended medical technologies, activities carried out under health policy programs, and the conditions for implementing these programs, concerning the prevention of lymphedema after breast cancer treatment
The recommendation is an update of Recommendation No. 11/2020 of November 30, 2020. of the President of the Agency for Health Technology Assessment and Tariff System on recommended medical technologies, activities carried out under health policy programs, and the conditions for implementing these programs, concerning the prevention of lymphedema after breast cancer treatment in accordance with Article 48aa(8) of the Act on healthcare services financed from public funds.
The recommendation contains a model solution for a given health problem – Prevention of lymphedema after breast cancer treatment.
The recommendation exempts local government units from the obligation to submit a health policy program prepared in accordance with its content for review.
Thus, the recommendation serves as a model for programs prepared by local government units for this health problem.
The President of the Agency recommends that health policy programs include an information campaign, training for medical personnel, health education for women with breast cancer (including their loved ones) both before and after oncological treatment, qualifying visits with an assessment of the risk of lymphedema, rehabilitation interventions for women with symptoms of lymphedema, dietary and psychological consultations, and a follow-up visit.
The President of the Agency does not recommend the use of other medical technologies, activities, and conditions of implementation within the framework of health policy programs than those included in this document and inconsistent with the implemented “Comprehensive oncological care for beneficiaries with breast cancer.”
Therefore, from November 28, 2025, in order to prepare PPZs for the prevention of lymphedema after breast cancer treatment, the provisions of recommendation No. 179/2025 should be taken into account, and then a statement of compliance of the PPZ draft with this recommendation should be sent to the Agency pursuant to Article 48aa(11) of the Act.
There is no need to modify the PPZ currently in force, which entered into force before the publication of recommendation 179/2025. It is not possible to continue future editions of the PPZ in unchanged form.